IP Library › Granted Patent US 12,497,440
Granted Patent B2
US 12,497,440 · App. 18/349,678 · Granted Dec 16, 2025

CS1 targeted chimeric antigen receptor-modified T cells

Inventors: Xiuli Wang (Temple City, CA); Stephen J. Forman (Duarte, CA)
Assignee: City of Hope
C07K14/70521A61K40/11A61K40/31A61K40/42C07K14/35C07K14/705C07K14/7051C07K14/71C07K16/2803C07K16/2896C12N5/0636C12N5/0637C12N5/0638C07K2317/526C07K2317/53C07K2317/622C07K2319/02C07K2319/03C07K2319/033C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,440
App. No.
18/349,678
Granted
Dec 16, 2025
Kind
B2
Abstract

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

Claims (26)

1 . A nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) targeting CS1, wherein the CAR comprises:

(a) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 9; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21;

(b) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 9; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21;

(c) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 11; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21;

(d) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 11; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21;

(e) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 2; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21; or

(f) a CS1 scFv comprising the amino acid sequence of SEQ ID NO: 1; a spacer domain comprising the amino acid sequence of SEQ ID NO: 2; a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 15; a co-signaling domain comprising the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain comprising the amino acid sequence of SEQ ID NO: 21.

2 . The nucleic acid molecule of claim 1 , wherein the CAR comprises:

(a) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 9; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21;

(b) a CS1 scFv consisting of the amino acid SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 9; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21;

(c) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 11; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21;

(d) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 11; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21;

(e) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 2; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 16; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 24; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21; or

(f) a CS1 scFv consisting of the amino acid sequence of SEQ ID NO: 1; a spacer domain consisting of the amino acid sequence of SEQ ID NO: 2; a transmembrane domain consisting of the amino acid sequence of SEQ ID NO: 15; a co-signaling domain consisting of the amino acid sequence of SEQ ID NO: 23; and a CD3ζ signaling domain consisting of the amino acid sequence of SEQ ID NO: 21.

3 . A population of human T cells harboring the nucleic acid molecule of claim 1 .

4 . The population of human T cells of claim 3 , wherein at least 20%, 30%, 40%, 50%, 60%, 70% or 80% of the transduced human T cells are central memory T cells.

5 . The population of human T cells of claim 4 , wherein at least 10% or 20% of the transduced central memory T cells are CD4+.

6 . The population of human T cells of claim 4 , wherein at least 10% or 20% of the transduced central memory T cells are CD8+.

7 . The population of human T cells of claim 4 , wherein at least 10% of the central memory T cells are CD4+ and at least 10% are CD8+.

8 . The population of human T cells of claim 7 , wherein at least 30% of the transduced human T cells are central memory T cells.

9 . A population of human T cells harboring the nucleic acid molecule of claim 2 .

10 . The population of human T cells of claim 9 , wherein at least 20%, 30%, 40%, 50%, 60%, 70% or 80% of the transduced human T cells are central memory T cells.

11 . The population of human T cells of claim 10 , wherein at least 10% or 20% of the transduced central memory T cells are CD4+.

12 . The population of human T cells of claim 10 , wherein at least 10% or 20% of the transduced central memory T cells are CD8+.

13 . The population of human T cells of claim 10 , wherein at least 10% of the central memory T cells are CD4+ and at least 10% are CD8+.

14 . The population of human T cells of claim 13 , wherein at least 30% of the transduced human T cells are central memory T cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: WANG, XIULI; FORMAN, STEPHEN J.
To: CITY OF HOPE
Reel/Frame 064207/0407 →
Continuity (4)
Continuation 16992361 · Aug 13, 2020
Continuation 15533153
Provisional Application 62088423 · Dec 5, 2014
Related Publication 20240009288A1 · Jan 11, 2024
References Cited (49)
US 6136957A · Nicola et al. · 2000 [cited by applicant]
US 8084026B2 · Glaser et al. · 2011 [cited by applicant]
US 8551715B2 · Gurney et al. · 2013 [cited by applicant]
US 10358494B2 · Yu et al. · 2019 [cited by applicant]
US 10821161B2 · Wang · 2020 [cited by examiner]
US 11730797B2 · Wang · 2023 [cited by examiner]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20160075784A1 · Yu et al. · 2016 [cited by applicant]
US 20160333108A1 · Forman et al. · 2016 [cited by applicant]
US 20170360910A1 · Wang et al. · 2017 [cited by applicant]
US 20200188432A1 · Wang et al. · 2020 [cited by applicant]
US 20210170001A1 · Wang et al. · 2021 [cited by applicant]
BR 112016017806 · 2017 [cited by applicant]
CN 101313069 · 2008 [cited by applicant]
RU 2487888 · 2013 [cited by applicant]
RU 2515108 · 2014 [cited by applicant]
WO WO2007047829 · 2007 [cited by applicant]
WO WO2007060406 · 2007 [cited by applicant]
WO WO2013123061 · 2013 [cited by applicant]
WO WO2013142034 · 2013 [cited by applicant]
WO WO2013151762 · 2013 [cited by applicant]
WO WO2014179759 · 2014 [cited by applicant]
WO WO2015121454 · 2015 [cited by applicant]
WO WO2015166056 · 2015 [cited by applicant]
Berger et al., “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,” J Clin Invest., 2008, 118(1):294-305. [cited by applicant]
Chien et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism,” Proc Natl Acad Sci USA., Jul. 1989, 86(14):5532-5536. [cited by applicant]
Chu et al., “CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma,” Leukemia, Sep. 26, 2013, 28(4):917-927. [cited by applicant]
Chu et al., “Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells,” Clin Cancer Res., Aug. 1, 2014, 20(15):3989-4000. [cited by applicant]
Edelman et al., “The covalent structure of an entire γG immunoglobulin molecule.” Proc Natl Acad Sci USA, May 1, 1969, 63(1):78-85. [cited by applicant]
European Office Action in EP Application No. 15819937.2 dated Sep. 20, 2018, 6 pages. [cited by applicant]
Galetto et al., “Abstract 2289: Allogenic TCRa/CS1 double knockout T-cells bearing an anti-CS1 chimeric antigen receptor: An improved immunotherapy approach for the treatment of multiple myeloma,” AACR 107th Annual Meet… [cited by applicant]
Galetto et al., “Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells fo… [cited by applicant]
Hsi et al., “CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.” Clin Cancer Res., May 1, 2008, 14(1):2775-84. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2015/064303, mailed on Jun. 15, 2017, dated Jun. 6, 2017, 2 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2015/064303, mailed on Apr. 25, 2016, 15 pages. [cited by applicant]
Jena et al., “Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials,” PLoS One., 2013, 8(3):e57838. [cited by applicant]
Kalos et al., “Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology,” Immunity, 2013, 39(1):49-60. [cited by applicant]
Lipowska-Bhalla et al., “Targeted Immunotherapy of cancer with CAR T cells: achievements and challenges,” Cancer Immunol Immunother., Jul. 2012, 61(7):953-962. [cited by applicant]
Mathur et al., “Abstract 502: Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma,” Blood, 2017, 130:15 pages. [cited by applicant]
Mathur et al., “Universal SLAMF7-Specific CAR T-Cells as Treatment for Multiple Myeloma,” Blood, 2017, 130(Supplement 1):502. [cited by applicant]
Mchayleh et al., “Chimeric Antigen Receptor T-Cells: The Future is Now,” J. Clin. Med., 2019, 8: 207-210. [cited by applicant]
Milone et al., “Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo,” Mol Ther., Aug. 2009, 17(8):1453-1464. [cited by applicant]
Ohno et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH,” Proc Natl Acad Sci USA., May 1985, 82(9):2945-2949. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA., Mar. 1982, 79(6):1979-1983. [cited by applicant]
Singer, “Geny and Genomy,” Moscow, 1998, vol. 1, p. 63 Non-English Translation. [cited by applicant]
Tai et al., “Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu,” Blood, 2008, 112:1329-1337. [cited by applicant]
Till et al., “CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results,” Blood, 2012, 119(17):3940-3950. [cited by applicant]
Vinay et al., “4-1BB Signaling Beyond T Cells,” Cell Mol Immun., Jul. 2011, 8(4):281-284. [cited by applicant]
Wang et al., “Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma,” Clin. Cancer Res., Jan. 1, 2018, 24(1):106-119. [cited by applicant]